Cargando…

Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies

BACKGROUND: Cystic fibrosis (CF) is a genetic, multisystemic, progressive and life-shortening disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Different genotypes have been linked to variations in disease progression among people with CF. The burden of illness (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bresnick, Kathryn, Arteaga-Solis, Emilio, Millar, Stefanie J, Laird, Glen, LeCamus, Cecile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Cystic Fibrosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640656/ https://www.ncbi.nlm.nih.gov/pubmed/34857524 http://dx.doi.org/10.1136/bmjresp-2021-000998

Ejemplares similares

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018)

Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database
por: Mehta, Zumi, et al.
Publicado: (2021)

Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
por: Keogh, Ruth H, et al.
Publicado: (2022)

International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety
por: Quittner, Alexandra L, et al.
Publicado: (2016)

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis
por: Kenny, S L, et al.
Publicado: (2014)

Coil embolisation for massive haemoptysis in cystic fibrosis
por: Dohna, Martha, et al.
Publicado: (2021)

Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis
por: Gray, Robert D, et al.
Publicado: (2018)

Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis
por: Useckaite, Zivile, et al.
Publicado: (2020)

Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022)

Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis
por: Knibbs, Luke D, et al.
Publicado: (2014)

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
por: Alton, Eric W F W, et al.
Publicado: (2017)

Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test
por: Minso, Rebecca, et al.
Publicado: (2020)

CNS imaging studies in cystic fibrosis patients presenting with sudden neurological events
por: Ellis, Samantha, et al.
Publicado: (2019)

Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age?
por: Thia, Lena P, et al.
Publicado: (2014)

Porphyromonas, a potential predictive biomarker of Pseudomonas aeruginosa pulmonary infection in cystic fibrosis
por: Keravec, Marlène, et al.
Publicado: (2019)

Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales
por: Schlüter, Daniela K, et al.
Publicado: (2019)

Acceptability of patient reported outcome measures (PROMs) in a cystic fibrosis data registry
por: Ratnayake, Irushi, et al.
Publicado: (2021)

Longitudinal lung clearance index and association with structural lung damage in children with cystic fibrosis
por: Svedberg, Marcus, et al.
Publicado: (2023)

Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants
por: Nguyen, The Thanh-Diem, et al.
Publicado: (2014)

Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis
por: Hannon, David, et al.
Publicado: (2014)

How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey
por: Smith, Sherie, et al.
Publicado: (2020)

Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians
por: Currie, Grace, et al.
Publicado: (2021)

Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis
por: Horsley, Alex R, et al.
Publicado: (2022)

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023)

Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis
por: Wainwright, C E, et al.
Publicado: (2009)

Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age
por: Byrnes, Catherine Ann, et al.
Publicado: (2013)

Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis
por: Dorkin, Henry L, et al.
Publicado: (2015)

Associations between genetics, medical status, physical exercise and psychological well-being in adults with cystic fibrosis
por: Backström-Eriksson, Lena, et al.
Publicado: (2016)

What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment?
por: Calthorpe, Rebecca J, et al.
Publicado: (2020)

Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study
por: Schlüter, Daniela K, et al.
Publicado: (2020)

Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data
por: Schlüter, Daniela K, et al.
Publicado: (2022)

Feasibility of dynamic chest radiography to calculate lung volumes in adult people with cystic fibrosis: a pilot study
por: FitzMaurice, Thomas Simon, et al.
Publicado: (2023)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Survival models to support shared decision-making about advance care planning for people with advanced stage cystic fibrosis
por: Hajizadeh, Negin, et al.
Publicado: (2021)

Short-term comparative study of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis
por: Osman, Leyla P, et al.
Publicado: (2009)

Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis
por: Jackson, Abaigeal D, et al.
Publicado: (2011)

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
por: Schuster, Antje, et al.
Publicado: (2013)

Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung
por: Tagalakis, Aristides D, et al.
Publicado: (2018)

Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial
por: Wildman, Martin J, et al.
Publicado: (2022)

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bmbmhus2n05tfltfqugo4n0bes